Original ArticlesPulmonary Arterial Capacitance Index Is a Strong Predictor for Adverse Outcome in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension
Section snippets
Methods
We retrospectively reviewed hemodynamic data evaluated by cardiac catheterization and clinical data of 72 children diagnosed with idiopathic and heritable PAH. All children (18 years or younger of age at diagnosis) were followed at Toho University Omori Medical Center (Tokyo, Japan) between 1998 and 2015. Patients with associated PAH due to congenital heart disease, secondary to left-sided obstructive lesions (pulmonary venous hypertension), or persistent pulmonary hypertension of the newborn
Results
Table I presents the clinical characteristics of the pediatric patients. Overall, 55 patients with idiopathic PAH and 17 with heritable PAH were enrolled. The age at diagnosis was 9.8 ± 3.7 years, with 38 male and 34 female patients. In all, 50 children (69%) were administrated epoprostenol infusion therapy during follow-up, and the remaining 22 children received oral vasodilators.
Discussion
We found that PACi had a significant correlation with disease severity including hemodynamic variables, BNP levels, 6MWD, and NYHA functional class and predicted adverse outcomes. The capacitance is the distensibility of the pulmonary arterial tree and is an important component of RV workload. Although normal pulmonary vessels have the capacity to dilate, in PAH pulmonary arterial capacitance is diminished or lost, leading to increased pulmonary artery pressure and RV hypertrophy. As RV
References (18)
Idiopathic pulmonary hypertension
Am Heart J
(1963)- et al.
Primary pulmonary hypertension: insights into pathogenesis from epidemiology
Chest
(1998) - et al.
Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension
J Am Coll Cardiol
(2006) - et al.
Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction
JACC Heart Fail
(2015) - et al.
Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival
Am Heart J
(2011) - et al.
Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension
Int J Cardiol
(2013) - et al.
Direct quantitation of right and left ventricular volumes with nuclear magnetic resonance imaging in patients with primary pulmonary hypertension
J Am Coll Cardiol
(1992) - et al.
The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension
J Am Soc Echocardiogr
(2006) - et al.
Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension
Am Heart J
(2008)
Cited by (21)
Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension
2018, ChestCitation Excerpt :These findings warrant further confirmation in other PH populations. Several previous studies have reported the prognostic importance of C (1/stiffness) in precapillary PH from various etiologies,7-10,33,34 but the relatively limited number of patients included and the lack of independent testing of the contribution of stroke volume per se has been strengthened.19 Our study was a subgroup of a previously published cohort, and the survival results must be viewed as essentially redundant rather than confirmatory.
Characteristics of the pulmonary circulation in infants with complete atrioventricular septal defect
2021, Cardiology in the YoungMonitoring of Hemodynamics With Right Heart Catheterization in Children With Pulmonary Arterial Hypertension
2023, Journal of the American Heart Association
Supported by the Jayden DeLuca Foundation, the Leah Bult Foundation, Colorado Clinical Translational Science Institute (UL1 TR001082), National Center for Research Resources, and National Institutes of Health. The University of Colorado contracts with Actelion, Bayer, Lilly, and United Therapeutics. D.I. serves as a member of the Gilead Sciences Research Scholars Program. The other authors declare no conflicts of interest.